Moneycontrol
HomeNewsBusinessStocksCRISIL assigns valuation grade of 5/5 to Plethico Pharma
Trending Topics
LG Electronics IPO Allotment Status
Canara HSBC Life IPO GMP
Midwest IPO Price
WeWork Share Price
Silver ETF

CRISIL assigns valuation grade of 5/5 to Plethico Pharma

CRISIL Research has come out with its report on Plethico Pharmaceuticals. The research firm has initiated coverage on Plethico Pharmaceuticals with a Valuation Grade of ‘5/5’ and maintain the fair value of Rs 530 per share.

April 26, 2011 / 19:09 IST
Story continues below Advertisement
Remove Ad


CRISIL Research has come out with its report on Plethico Pharmaceuticals. The research firm has initiated coverage on Plethico Pharmaceuticals with a Valuation Grade of

Read More

first published: Apr 26, 2011 07:00 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Follow Us On: Facebook twitter instagram linkedin telegram youtube
News
Business New Market New Stocks Income Tax Calculator Election Schedule 2024 India News Economy Mutual Funds Personal Finance IPO News Startups New USA Elections New
Features
Gold Rate Today Silver Rate Today Trending News Startups New National News MC Videos MC You Tube
Tools
SIP Calculator 2 SIP Calculator 3 SIP Calculator 1 New SIP Calculator 4
Specials
PowerYourTrade Master Your Money Game Changers
Network 18 Sites
News18 Firstpost CNN News18 CNBC TV18 Forbes History TV18
Personal Finance
Home Loans up to 50 Lakhs Credit Cards Lifetime Free Finance Tracker Fixed Deposits Fixed Deposit Comparison Fixed Income Account Aggregator
Quick Links
About Us New Contact Us Advisory Alert New Advertise with Us New Disclaimer Privacy Policy Cookie Policy Terms & Conditions Careers Financial Terms (Glossary) Analytical & Information Tool New
Download MC Apps:

Copyright © Network18 Media & Investments Limited. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.